Compound preparation for reducing toxic effect of zearalenone of bred animals as well as preparation method and application of compound preparation

Abstract

The invention provides a compound preparation for reducing the toxic effect of zearalenone of bred animals as well as a preparation method and application of the compound preparation, and belongs to the technical field of medicines for livestock and poultry. The invention provides a compound preparation for reducing the toxic effect of zearalenone of bred animals. The compound preparation is prepared from the following components in parts by weight: 40 to 50 parts of total flavonoids of radix astragali seu hedysari, 0.1 to 0.4 part of selenium-enriched yeast, 10 to 15 parts of modified montmorillonite and 1 to 4 parts of vitamin C. The four components in the compound preparation are mutually matched and synergistically synergized to reduce the toxic effect of zearalenone and resist zearalenone poisoning of bred animals, and the compound preparation has high safety, so that the production performance of the bred animals and the quality of animal-derived products are improved, the green and healthy development of animal husbandry is promoted, the preparation method is simple, the cost is low, and the compound preparation is suitable for industrial production. The method is suitable for large-scale production and application.

Description

Technical Field

[0001] The present invention relates to the technical field of livestock and poultry medicines, and in particular to a compound preparation for reducing the toxicity of zearalenone in farmed animals, and a preparation method and application thereof. Background Art

[0002] Zearalenone is a metabolite of zearalenone fungi, which has estrogenic effects and mainly acts on the reproductive system. It can increase the estrogen level of livestock, poultry and experimental animals, causing abnormal reproductive function or even death of animals. Poisoning in pregnant animals can cause miscarriage, stillbirth and teratogenesis. Zearalenone is mainly found in grains such as corn, wheat, and sorghum that are susceptible to fungal contamination. The direct cause of zearalenone poisoning in farmed animals is the ingestion of moldy feed and these raw materials. Zearalenone contamination can occur in the production, processing, transportation and storage of feed and raw materials. Although strict hygiene standards and testing systems have been formulated for effective control, zearalenone contamination cannot be completely avoided due to environmental factors, resulting in cases of poisoning in farmed animals occurring all year round, causing huge economic losses to the animal husbandry industry. Therefore, controlling and reducing the harm of zearalenone to animal health during the breeding process is an important and arduous task.

[0003] At present, there is no specific drug for the treatment of zearalenone poisoning in farmed animals. Veterinary clinics often adopt methods such as stopping feeding suspicious feeds and inducing vomiting, gastric lavage, and nutritional supplementation to deal with it. In addition, most clinical cases of zearalenone poisoning are chronic poisoning, with a certain amount of residue and accumulation in the body. Generally, it takes up to half a year for the toxin to be metabolized out of the body, causing great losses and a long time.

[0004] Zearalenone mainly causes reproductive toxicity, and its toxic mechanism is to induce a strong oxidative stress response in the reproductive organs of livestock and poultry, leading to oxidative damage and cell apoptosis, thus affecting reproductive performance. Therefore, taking the toxic effect of zearalenone as a breakthrough, adding drugs to the feed of farmed animals to prevent reproductive damage can effectively control the harm caused by zearalenone to animals.

[0005] In recent years, the research and application of natural active ingredients have shown a trend of diversification and deepening, especially in the field of medicine, showing great potential and broad application prospects:

[0006] (1) Astragalus is the dried root of Astragalus mongolica or Astragalus membranaceus, a plant of the Leguminosae family. It is sweet and warm in nature and is one of the most commonly used bulk medicinal materials. It was first recorded in Shennong's Herbal Classic. It has the effects of replenishing qi, strengthening the exterior, diuresis, detumescence, detoxification, and tissue regeneration. Astragalus can be added to animal feed as a feed raw material for a long time, and is also an indispensable raw material for medicine in breeding. Astragalus total flavonoids, as one of the most beneficial components in Astragalus, has multiple pharmacological effects such as antioxidant, anti-tumor, anti-inflammatory, and immunomodulatory.

[0007] (2) Selenium is one of the essential trace elements for animal health and is widely involved in various physiological and biochemical activities in the body. In addition, selenium has antioxidant, immune-enhancing, anti-inflammatory, and antiviral functions, which are of key significance to animal health.

[0008] (3) The most widely used application of modified montmorillonite in livestock and poultry production is to improve feed quality and adsorb and detoxify molds and mycotoxins in the gastrointestinal tract. Its advantage is that it can fix molds and mycotoxins, does not cause secondary infection to livestock and poultry, and is excreted from the body through the digestive tract after a period of time.

[0009] (4) Vitamin C has the functions of detoxification, assisting in regulating autoimmune organs, accelerating nutrient absorption, and promoting growth and development.

[0010] Compound preparations are a common type of medicine in veterinary clinics. Compared with single medication, compound preparations can significantly make up for the shortcomings of single medication and effectively shorten the treatment cycle. Therefore, the present invention uses four medicinal ingredients, namely, astragalus total flavonoids, trace element selenium, modified montmorillonite and vitamin C, to design and prepare a compound preparation that reduces the toxicity of zearalenone in farmed animals and applies it to feed. In the breeding process, the zearalenone can effectively control the harm to animals, which has important production practice significance and application prospects. Summary of the invention

[0011] The purpose of the present invention is to provide a compound preparation for reducing the toxic effect of zearalenone in farmed animals, and a preparation method and application thereof, so as to solve the problem of medication for zearalenone poisoning in animals.

[0012] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0013] The invention provides a compound preparation for reducing the toxic effect of zearalenone in farmed animals. The compound preparation comprises the following components in parts by weight: 40-50 parts of total astragalus flavonoids, 0.1-0.4 parts of selenium-enriched yeast, 10-15 parts of modified montmorillonite and 1-4 parts of vitamin C.

[0014] Preferably, the purity of the total flavonoids of Astragalus membranaceus is ≥90%, and the main components are calycosin, calycosin and formononetin.

[0015] Preferably, the selenium in the selenium-enriched yeast exists in the form of selenomethionine and selenocysteine, and the selenium content is 1000-2000 ppm, wherein the organic selenium content is ≥95%.

[0016] Further preferably, the selenium in the selenium-enriched yeast exists in the form of selenomethionine and selenocysteine, and the selenium content is 1000 ppm or 2000 ppm, wherein the organic selenium content is ≥95%.

[0017] Still further preferably, the selenium in the selenium-enriched yeast exists in the form of selenomethionine and selenocysteine, the selenium content is 2000 ppm, and the organic selenium content is ≥95%.

[0018] The present invention also provides a method for preparing the compound preparation, comprising the following steps: taking the astragalus total flavonoids, selenium-enriched yeast, modified montmorillonite and vitamin C, crushing and screening them respectively, and then mixing them according to weight parts to obtain the compound preparation.

[0019] Preferably, the mesh size of the sieving is 50 to 100 meshes.

[0020] Further preferably, the mesh size of the sieving is 50 mesh or 100 mesh.

[0021] Still further preferably, the mesh size of the sieving is 100 meshes.

[0022] Preferably, the mixing is performed using a three-dimensional mixer, the rotation speed of the three-dimensional mixer is 40 to 60 rpm, and the mixing time is 20 to 30 minutes.

[0023] Further preferably, the mixing is performed using a three-dimensional mixer, the rotation speed of the three-dimensional mixer is 50 rpm, and the mixing time is 30 min.

[0024] The present invention also provides an application of the compound preparation or the compound preparation obtained according to the preparation method in preparing a drug for reducing the toxic effect of zearalenone on farmed animals.

[0025] Preferably, the compound preparation is added to the diet for animal intake, and the addition amount of the compound preparation in the diet is 1-3wt%.

[0026] The compound preparation for reducing the toxicity of zearalenone in the present invention has the following beneficial effects:

[0027] (1) Zearalenone is toxic to many organs and physiological systems of animals, and is most toxic to the reproductive system. Based on the process and mechanism of zearalenone toxicity, the present invention innovatively screens out components of astragalus total flavonoids, selenium, modified montmorillonite and vitamin C from four categories of active ingredients of traditional Chinese medicine, trace elements, adsorbents and vitamins, and then scientifically proportions them to form a compound preparation that reduces the toxic effects of zearalenone on farmed animals. The compound preparation is used to treat zearalenone poisoning in experimental mice, pigs and chickens, and has significant efficacy.

[0028] (2) The ingredients of the compound preparation of the present invention, total flavonoids of Astragalus, selenium, modified montmorillonite and vitamin C, have the advantages of abundant resources, natural sources, comprehensive functions, high safety, low toxicity and side effects, low resistance and low residue, and do not contain antibiotics. When used for the treatment of animals poisoned by zearalenone, the compound preparation not only can exert significant therapeutic effects, but also has high safety, thereby improving the production performance of farmed animals and the quality of animal-derived products, and promoting the green and healthy development of animal husbandry. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 It is the content of ROS, an oxidative stress indicator, in the testes of male mice and ovarian tissues of female mice in each group in Example 2. Normal is the normal group; ZEA is the zearalenone group; C-1 is the compound preparation group 1; C-2 is the compound preparation group 2; C-3 is the compound preparation group 3.

[0030] Figure 2 It is the content of ROS, an oxidative stress indicator, in the testes of male mice and the ovarian tissues of female mice in each group in Example 3. Normal is the normal group; ZEA is the zearalenone group; TFA is the total flavonoids of astragalus group; SEY is the selenium-enriched yeast group; MM is the modified montmorillonite group; VC is the vitamin C group; C-3 is the compound preparation 3 group.

[0031] Figure 3 These are tissue sections of the testicles of male mice and ovaries of female mice in each group in Example 4 (HE staining, 200×).

[0032] Figure 4 The expression levels of inflammatory factor mRNA in the testis of male mice and the ovarian tissue of female mice in each group in Example 4. The upper figure is the testis, the lower figure is the ovary; Normal is the normal group; ZEA is the zearalenone group; C-3 is the compound preparation group 3. DETAILED DESCRIPTION

[0033] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0034] Example 1

[0035] Preparation of compound preparations:

[0036] The total flavonoids of Astragalus used to prepare the compound preparation in this embodiment were purchased from Chengdu Ruifensi Biotechnology Co., Ltd., with a purity of ≥90%, and the main components were calycosin isoflavone glycosides, calycosin isoflavones and formononetin; selenium-enriched yeast was purchased from Angel Yeast Co., Ltd., in which selenium existed in the form of selenomethionine and selenocysteine, with a selenium content of 2000 ppm, and the organic selenium content was ≥95%; modified montmorillonite was purchased from Beijing Yimeishi Biotechnology Co., Ltd.; and vitamin C was purchased from Leshengyuan Biotechnology Co., Ltd.

[0037] (1) The four medicinal ingredients of the compound preparation, namely, total flavonoids of astragalus, selenium-enriched yeast, modified montmorillonite and vitamin C, were taken and crushed through a 100-mesh sieve. The sieved materials were accurately weighed according to the proportion (400 g of total flavonoids of astragalus, 1 g of selenium-enriched yeast, 100 g of modified montmorillonite and 10 g of vitamin C), and then put into a three-dimensional mixer for mixing. The speed was set to 50 rpm and the mixture was mixed for 30 min to obtain the compound preparation 1. The mixture was sealed under sterile conditions and stored in a refrigerator for later use.

[0038] (2) The four medicinal ingredients of the compound preparation, namely, total flavonoids of astragalus, selenium-enriched yeast, modified montmorillonite and vitamin C, were taken and crushed through a 100-mesh sieve. The sieved materials were accurately weighed according to the proportion (450 g of total flavonoids of astragalus, 2.5 g of selenium-enriched yeast, 125 g of modified montmorillonite and 25 g of vitamin C), and then put into a three-dimensional mixer for mixing. The speed was set to 50 rpm and the mixture was mixed for 30 min to obtain the compound preparation 2. The mixture was sealed under sterile conditions and stored in a refrigerator for later use.

[0039] (3) The four medicinal ingredients of the compound preparation, namely, total flavonoids of astragalus, selenium-enriched yeast, modified montmorillonite and vitamin C, were taken and crushed through a 100-mesh sieve. The sieved materials were accurately weighed according to the ratio (total flavonoids of astragalus is 500 g, selenium-enriched yeast is 4 g, modified montmorillonite is 150 g, and vitamin C is 40 g). The mixture was then put into a three-dimensional mixer for mixing. The speed was set to 50 rpm. The mixture was mixed for 30 min to obtain the compound preparation 3. The mixture was sealed under sterile conditions and stored in a refrigerator for later use.

[0040] Example 2

[0041] Three batches of compound preparations prepared in Example 1 were used for mouse experiments:

[0042] After 60 mice (half male and half female, tested separately) were adaptively fed for 1 week, they were randomly divided into a normal group, a zearalenone group, a compound preparation group 1, a compound preparation group 2, and a compound preparation group 3. The normal group mice were gavaged with olive oil every day, and the mice in the other groups were gavaged with 20 mg / kg zearalenone (dissolved in olive oil), and the gavage volume was 200 μL. In addition to the normal group and the zearalenone group, the compound preparations 1, 2, and 3 groups were given 2 wt% of the compound preparations 1, 2, and 3 prepared in Example 1 in the diet. After the 14-day experiment, the content of oxidative stress index ROS in the testis of male mice and the ovarian tissue of female mice was detected by a kit.

[0043] The results showed that compared with the zearalenone group, the compound preparations 1, 2, and 3 of the present invention could reduce the content of ROS, an indicator of oxidative stress, in the testis of male mice and the ovary of female mice caused by zearalenone. The content of ROS in the compound preparation 3 group was the lowest, but there was no significant difference among the compound preparation groups (see Figure 1 , compared with the normal group, ** Indicates that the difference is extremely significant (P﹤0.01); compared with the zearalenone group, ## Indicates that the difference is extremely significant (P﹤0.01).

[0044] In summary, the compound preparation of the present invention has no significant difference in effect within the weight range of 40-50 parts of total flavonoids of astragalus, 0.1-0.4 parts of selenium-enriched yeast, 10-15 parts of modified montmorillonite, and 1-4 parts of vitamin C, and can effectively alleviate the oxidative stress damage of the reproductive system of mice caused by zearalenone. In addition, the components of the compound preparation are preferably: 50 parts of total flavonoids of astragalus, 0.4 parts of selenium-enriched yeast, 15 parts of modified montmorillonite, and 4 parts of vitamin C.

[0045] Example 3

[0046] In order to verify the synergistic effect of the four medicinal ingredients in the compound preparation for reducing the toxicity of zearalenone in the present invention, each individual ingredient and the compound preparation were subjected to a mouse comparative test, and the proportion of each component in the compound preparation 3 in Example 1 was used as the experimental drug:

[0047] After 1 week of adaptive feeding, 84 mice (half male and half female, tested separately) were randomly divided into a normal group, a zearalenone group, a total flavonoids group of astragalus, a selenium-enriched yeast group, a modified montmorillonite group, a vitamin C group, and a compound preparation group.

[0048] The normal group mice were gavaged with olive oil every day, and the other groups of mice were gavaged with 20 mg / kg zearalenone (dissolved in olive oil), and the gavage volume was 200 μL. Except for the normal group and the zearalenone group, the above groups were given 2wt% of the corresponding drugs in the diet. After the 14-day experiment, the content of oxidative stress indicator ROS in the testis of male mice and the ovarian tissue of female mice was detected by a kit.

[0049] The results showed that compared with the zearalenone group, total flavonoids of Astragalus, selenium-enriched yeast, modified montmorillonite, vitamin C, and the compound preparation could inhibit the excessive accumulation of ROS, an indicator of oxidative stress, in the testis of male mice and the ovary of female mice caused by zearalenone to varying degrees, and the ROS content in the compound preparation group of the present invention was the lowest (see Figure 2 , compared with the normal group, ** Indicates that the difference is extremely significant (P﹤0.01); compared with the zearalenone group, # Indicates significant difference (P﹤0.05), ## The difference is extremely significant (P < 0.01). This indicates that the components in the compound preparation of the present invention have a synergistic inhibitory effect on the oxidative stress damage of the reproductive system of mice caused by zearalenone, greatly improving the antioxidant effect of the compound preparation.

[0050] Example 4

[0051] In order to further comprehensively verify the intervention effect of the compound preparation of the present invention for reducing the toxicity of zearalenone, the compound preparation 3 described in Example 1 was subjected to a mouse test:

[0052] 60 mice (half male and half female, tested separately) were adaptively fed for 1 week and then randomly divided into a normal group, a zearalenone group, and a compound preparation group. The normal group mice were gavaged with olive oil daily, and the other groups of mice were gavaged with 20 mg / kg zearalenone (dissolved in olive oil), and the gavage volume was 200 μL. The compound preparation group was given 2wt% of the compound preparation in the diet according to Example 1 for 3. After the 14-day experiment, the weight of each group of mice was counted (for calculating the organ index), and the testicles and epididymis of male mice and the organ index of female ovaries were measured; the testicular tissue of male mice and the ovarian tissue of female mice were pathologically analyzed by visual observation and pathological sections; the expression of inflammatory cytokines TNF-α, IL-1β, and IL-6 mRNA in the testicles and ovaries was detected by RT-qPCR; the content of oxidative stress index MDA in the testicular and ovarian tissues of mice and the content of antioxidants SOD, CAT, and GSH-Px were detected by the kit.

[0053] The results showed that the compound preparation of the present invention can reduce the organ index of male mouse testis and female mouse ovary caused by zearalenone (see Table 1), improve the pathological changes of male mouse testis tissue and female mouse ovary tissue (see Table 2). Figure 3 ), inhibiting the overexpression of TNF-α, IL-1β, and IL-6 mRNA in the testis tissue of male mice and the ovarian tissue of female mice (see Figure 4 , compared with the normal group, ** Indicates that the difference is extremely significant (P﹤0.01); compared with the zearalenone group, # Indicates significant difference (P﹤0.05), ## The difference was extremely significant (P < 0.01), reducing the content of the oxidation index MDA in the testis tissue of male mice and the ovary of female mice caused by zearalenone, and increasing the content of antioxidants SOD, CAT, and GSH-Px (see Table 2). In summary, the compound preparation of the present invention can effectively alleviate the reproductive damage caused by zearalenone to mice.

[0054] Table 1. Organ index of male mouse testis and female mouse ovary

[0055]

[0056] Table 2. Oxidative stress indicators and antioxidant content in male mouse testes and female mouse ovaries

[0057]

[0058] Example 5

[0059] This example provides two clinical application cases of the compound preparation prepared by the present invention:

[0060] First, the indicators for determining the severity of zearalenone poisoning in farmed animals are given, mainly including:

[0061] (1) Clinical symptoms: observe whether the farmed animals have symptoms such as loss of appetite, vomiting, fever, red skin, restlessness, etc., whether the reproductive organs of livestock are edematous or prolapsed, and whether the poultry combs are swollen;

[0062] (2) Pathological changes: Pathological examination is used to observe whether the reproductive organs of farmed animals have inflammatory damage;

[0063] (3) Fertility: Assess whether the reproductive capacity of farmed animals has declined, such as whether livestock have experienced reduced mating efficiency, false pregnancy, miscarriage, stillbirth, and whether poultry have experienced reduced egg production.

[0064] Furthermore, based on the above indicators, farmed animals that only show clinical symptoms, no or mild pathological changes, and no impact on fertility are classified as mildly poisoned by zearalenone, and 1wt% of the compound preparation is added to the non-polluted diet for administration; farmed animals that show both clinical symptoms and obvious pathological changes but no impact on fertility are classified as moderately poisoned by zearalenone, and 2wt% of the compound preparation is added to the non-polluted diet for administration; farmed animals that show both clinical symptoms and obvious pathological changes and reduced fertility are classified as severely poisoned by zearalenone, and 3wt% of the compound preparation is added to the non-polluted diet for administration.

[0065] Application Case (I)

[0066] At a large-scale pig farm in Yanbian Korean Autonomous Prefecture, Jilin Province, sows on hand experienced prolonged estrus or pseudopregnancy, an increase in the number of stillbirths, and swelling, firmness, tension, and flushing of the vulva of sick pigs. Some pigs showed clinical manifestations such as vaginal prolapse and yellow or yellow-green loose stools, and their feed intake and body weight gradually decreased. At the same time, piglets also showed symptoms such as redness and swelling of the vulva after birth and diarrhea in the delivery room. After a week of treatment with a variety of anti-toxic, antibacterial and anti-dysentery drugs, the condition did not show significant improvement. After autopsy of the sick pigs, pathological changes in the reproductive system were mainly found, including congestion, bleeding, and swelling of the vaginal mucosa, edema of the uterus and ovaries, and accompanied by partial necrotic changes and bleeding in the liver and kidneys.

[0067] Clinical diagnosis: When inspecting the warehouse feed corn, it was found that there was a lot of mold in the stock corn. Based on the comprehensive clinical symptoms, pathological changes and laboratory test results, it was determined to be zearalenone poisoning.

[0068] Treatment method: Stop using feed made from moldy corn, and add 3wt% of the compound preparation 3 described in Example 1 to non-polluted feed.

[0069] Criteria for judging the therapeutic effect: The sow is considered cured when the symptoms of zearalenone poisoning, such as redness and swelling of the labia majora, early estrus, and abnormal defecation, have basically disappeared or completely disappeared.

[0070] Treatment results: After 7 days of treatment, no sows died and the cure rate was 32%; after 14 days of treatment, no sows died and the cure rate was 90% (see Table 3).

[0071] Table 3. Treatment of pigs poisoned by zearalenone

[0072]

[0073] Application Case (II)

[0074] At a laying hen farm in Siping City, Jilin Province, Hy-Line Brown laying hens around 350 days old began to show clinical symptoms such as decreased egg production and egg quality, hyperactivity, swollen combs, diarrhea, and decreased feed intake and weight. The farmers treated them for gastroenteritis and added intestinal antibiotics on their own, but the symptoms did not improve and tended to worsen day by day. The chickens began to die. Autopsy of the affected chickens showed edema and bleeding of the oviduct mucosa, accompanied by enlargement and bleeding of the liver.

[0075] Clinical diagnosis: Investigation revealed that the feed fed by the farmer was self-mixed and the corn used was aged corn, with some mold spots visible to the naked eye, suspected to be zearalenone poisoning.

[0076] Treatment method: immediately change the feeding material and add 3wt% of the compound preparation 3 described in Example 1 to the uncontaminated feed.

[0077] Criteria for judging therapeutic efficacy: Chickens can be judged as cured when the symptoms of zearalenone poisoning, such as swollen combs, diarrhea, decreased feed intake and weight, and decreased egg production rate and egg quality, have basically disappeared or completely disappeared.

[0078] Treatment results: After 7 days of treatment, the mortality rate of the infected laying hens was 1.5%, and the cure rate was 43.1%. After 14 days of treatment, the mortality of the infected laying hens was under control, with a total mortality rate of 1.9% and a cure rate of 92.0% (see Table 4).

[0079] Table 4. Treatment of chickens poisoned by zearalenone

[0080]

[0081] As can be seen from the above embodiments, the present invention provides a compound preparation for reducing the toxic effects of zearalenone, and its preparation method and application. The total flavonoids of Astragalus and selenium in the compound preparation provided by the present invention are both good antioxidants. The two alleviate the toxic effects of zearalenone from multiple levels such as inhibiting the oxidative damage of zearalenone to the animal body and inhibiting excessive inflammatory reactions, so as to minimize the damage caused by zearalenone to the animal; modified montmorillonite can adsorb zearalenone in the gastrointestinal tract of animals, reduce accumulation in the body, and protect the gastrointestinal mucosa; vitamin C, as a nutrient, mainly helps the body to excrete toxins, enhance immunity, improve reproductive performance, and promote growth and development. These four types of components cooperate with each other, coordinate and enhance synergy, reduce the toxic effects of zearalenone, and resist zearalenone poisoning in farmed animals.

[0082] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A compound preparation for reducing the toxicity of zearalenone in farmed animals, characterized in that: The invention comprises the following components in parts by weight: 40-50 parts of total astragalus flavonoids, 0.1-0.4 parts of selenium-enriched yeast, 10-15 parts of modified montmorillonite and 1-4 parts of vitamin C.

2. The compound preparation according to claim 1, characterized in that: The purity of the total flavonoids of Astragalus membranaceus is greater than or equal to 90%, and the main components are calycosin, calycosin and formononetin.

3. The compound preparation according to claim 2, characterized in that: The selenium in the selenium-enriched yeast exists in the form of selenomethionine and selenocysteine, and the selenium content is 1000-2000 ppm, wherein the organic selenium content is ≥95%.

4. A method for preparing the compound preparation according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: taking the total flavonoids of astragalus, selenium-enriched yeast, modified montmorillonite and vitamin C, crushing and screening them respectively, and then mixing them according to weight portions to obtain the compound preparation.

5. The preparation method according to claim 4, characterized in that: The mesh number of the sieving is 50 to 100 meshes.

6. The preparation method according to claim 5, characterized in that: The mixing is performed using a three-dimensional mixer, the rotation speed of the three-dimensional mixer is 40 to 60 rpm, and the mixing time is 20 to 30 minutes.

7. Use of the compound preparation according to any one of claims 1 to 3 or the compound preparation obtained by the preparation method according to any one of claims 4 to 6 in the preparation of a drug for reducing the toxic effect of zearalenone in farmed animals.

8. The use according to claim 7, characterized in that The compound preparation is added to the diet for the farmed animals to ingest, and the addition amount of the compound preparation in the diet is 1-3wt%.

Images